Coverage
-
August 25, 2026
Abbott Laboratories and a proposed class of shareholders have reached an $88.5 million settlement to resolve claims that the company misled investors about its safety practices ahead of the 2022 recall at its Sturgis, Michigan, infant formula plant, in a deal that comes a month after an Illinois federal judge tossed the suit.
1 other articles on this case.
View all »